₩33950.00
₩-250.00 (-0.73%)
End-of-day quote: 05/10/2024
KOSE:A009420
Hanall Biopharma Annual Report
| Year | Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2012 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
₩134.91B | ₩110.00B | ₩101.59B | ₩88.60B | ₩108.45B | ₩91.84B | ₩84.23B | ₩80.02B | ₩76.03B | |
| GM % | Gross Margin % |
|
55.62% | 56.25% | 59.29% | 57.08% | 57.80% | 53.27% | 50.58% | 45.62% | 46.37% | |
| OM | Operating Margin |
|
1.29% | 1.37% | 9.94% | 6.70% | 15.76% | 5.96% | 4.20% | -5.35% | -4.03% | |
| EPS | Earnings Per Share |
|
₩0.00 | ₩69.00 | ₩5.00 | ₩174.00 | ₩386.00 | ₩375.00 | ₩64.00 | ₩114.00 | ₩10.00 | ₩-79.00 |
| Div. | Dividends |
|
₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |
| PR % | Payout Ratio % |
|
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Sha. | Shares |
|
50.69m | 50.69m | 51.21m | 51.18m | 51.18m | 51.18m | 51.18m | 50m | 40.34m | |
| OCF | Operating Cash Flow |
|
₩29.64B | ₩25.20B | ₩839.87M | ₩929.29M | ₩20.49B | ₩-2994.39M | ₩42.14B | ₩-454.02M | ₩2.20B | |
| FCF | Free Cash Flow |
|
₩6.03B | ₩22.37B | ₩-3766.03M | ₩-1633.03M | ₩20.28B | ₩-4913.31M | ₩40.41B | ₩-2437.29M | ₩11.13M | |
| FCFS | Free Cash Flow Per Share |
|
₩403.32 | ₩344.92 | ₩-159.41 | ₩-126.23 | ₩238.68 | ₩-96.01 | ₩783.05 | ₩-81.68 | ₩-129.61 |
